The Institute for Regenerative and Cellular Medicine (IRCM) is a 501(3)(C) non-profit corporation created to validate regenerative and cellular medicine through Institutional Review Board (IRB) certification as well as collaborative and translational research.
The IRB the IRCM houses is registered with the U.S. Department of Health and Human Services (HHS), with a primary goal of providing ethical oversight of research to insure patient safety and the effectiveness of clinical protocols. The IRCM IRB is composed of a select group of PhDs with a background in stem cell research, physicians who work in the field, patient advocates, and professional privacy and regulation experts—all of whom are registered with the FDA.
As part of its IRB mission, IRCM provides interactive reviews of proposed research projects to make sure they are correctly designed to bring advanced treatments to patients without compromising safety, and that they comply with all existing federal regulations. IRCM prides itself on rapid response, and works to bring submissions into compliance as quickly as possible.
IRCM focuses primarily on individual investigators, to make sure they meet all necessary ethical and legal criteria for research, rather than protecting institutions. We are uniquely positioned to make determinations and help guide investigators (and sponsors) who wish to responsibly move the regenerative and cellular medicine industry forward. Our aim is to bring therapies from theory to practice, working with clinics, regulators, and patients.
Beyond guiding and validating studies in regenerative therapies, IRCM also facilitates collaborative research between physicians, scientists, academics and the cellular industry. A component of this is the collection of mega-data from physicians and researchers in order to build models of efficacy and compliance.
In addition, IRCM accepts and channels charitable donations to fund specific translational research, expediting the process of bringing treatments to patients.